Blocking mineralocorticoid receptor with spironolactone may have a wide range of therapeutic actions in severe COVID-19 disease

Crit Care. 2020 Jun 8;24(1):318. doi: 10.1186/s13054-020-03055-6.

Authors

Lucas Liaudet¹, Csaba Szabo²

Affiliations

¹ The Service of Adult Intensive Care Medicine, University Hospital Medical Center, Rue du Bugnon 46, 1011, Lausanne, Switzerland. lucas.liaudet@chuv.ch.
² The Department of Pharmacology, Faculty of Science and Medicine, University of Fribourg, 1700, Fribourg, Switzerland.

No abstract available

MeSH terms

COVID-19
Coronavirus Infections / drug therapy*
Humans
Mineralocorticoid Receptor Antagonists / therapeutic use*
Pandemics
Pneumonia, Viral / drug therapy*
Severity of Illness Index
Spironolactone / therapeutic use*

Substances

Mineralocorticoid Receptor Antagonists
Spironolactone